Guidelines Recommend
18F-FET PET Imaging With MRI for Glioma1,2

Actor portrayal

The guidelines below provide general recommendations1,2; however, 18F-FET (Pixclara®) is approved only for differentiation of recurrent or progressive glioma from treatment-related change3

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Evidence NCCN Category 2A1

Amino acid PET/CT or PET/MRI brain scanning

  • The most clinically established radiolabeled amino acid (AA) tracers used in the evaluation of both primary and secondary brain tumors include 11C-methyl-L-methionine (MET), O-(2-18Ffluoroethyl)-L-tyrosine (FET), and 3,4-dihydroxy-6-18-F-fluoro-L-phenylalanine (FDOPA)
  • When combined with anatomical MRI, these tracers significantly enhance diagnostic performance by improving lesion characterization, particularly in cases where conventional imaging is equivocal
  • According to the joint RANO, EANO, and SNMMI guidelines, AA PET may be utilized for:
    • delineating tumor extent
    • guiding stereotactic biopsy
    • improving radiotherapy planning through enhanced margin visualization
    • distinguishing tumor progression from treatment-related effects such as pseudoprogression or radionecrosis
  • Reported sensitivities and specificities for these applications often approach or exceed 90% across multiple studies

Joint EANM/EANO/RANO/SNMMI practice guidelines: common indications for PET imaging in glioma2

At primary diagnosis

  • Differentiation of grade 3 and 4 tumors from nonneoplastic lesions or grade 1 and 2 gliomas
  • Prognostication of gliomas
  • Definition of the optimal biopsy site (eg, site of maximum tracer uptake)
  • Delineation of tumor extent for surgery and radiotherapy planning

Diagnosis of tumor recurrence

  • Differentiation of glioma recurrence from treatment-induced changes (eg, pseudoprogression, radionecrosis)

Disease and therapy monitoring

  • Detection of malignant transformation in grade 1 and 2 gliomas
  • Response assessment during and after radiotherapy and/or chemotherapy
  • Differentiation of tumor response from pseudoresponse during antiangiogenic therapy

18F-FET has been approved for use in several countries and has over 20 years of real-world evidence to give you reliable results4

Pixclara® was well tolerated in 2 clinical trials.3

See Safety Data

18F-FET, 18F-fluoro-ethyl-tyrosine; CT, computed tomography; EANM, European Association of Nuclear Medicine; EANO, European Association of Neuro-Oncology; MRI, magnetic resonance imaging; NCCN, National Comprehensive Cancer Network; PET, positron emission tomography; RANO, Response Assessment in Neuro-Oncology; SNMMI, Society of Nuclear Medicine and Molecular Imaging.